Design Therapeutics Inc. (DSGN) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Design Therapeutics Inc. (NASDAQ: DSGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $10.68 (-3.44% 1D, market cap $692.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DSGN ranks #675 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DSGN carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.1%. By comparison, GYRE (Gyre Therapeutics Inc.) holds a D grade (47/100 RQD, P/E 72.3x, ROIC 25.4%, cap $714.8M) and WVE (Wave Life Sciences Inc.) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).
Per DSGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001807120), Design Therapeutics Inc. generated $0 in revenue, -$69.8M in net income, and -$54.6M in free cash flow against $226.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While DSGN currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.58) and Max Pain ($11.21) forces dealer call-delta covering toward $18.11.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Design Therapeutics Inc. (DSGN) dropped -3.44% to $10.68, trading at 41% of its 52-week range ($6.16 – $17.25). Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.
Seeking Alpha report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Singapore report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Australia report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DSGN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DSGN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Design Therapeutics Inc. (DSGN) ranks #675 by composite RQD confidence (35/100, grade D-) and #401 by equity capitalization ($692.2M). Within this direct 5-issuer industry benchmark cohort, GYRE leads on earnings valuation at 72.3x trailing P/E, while GYRE leads on capital efficiency and profitability with 25.4% ROIC and 95.4% gross margin. GYRE currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with DSGN at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DSGN
ACTIVE
Design Therapeutics Inc. | D- | 35/100 | — | — | -32.1% | -3.44% | $692.2M | Benchmark Subject |
| GYRE Gyre Therapeutics Inc. | D | 47/100 | 72.3x | 95.4% | 25.4% | -28.94% | $714.8M | /gyre-vs-dsgn → |
| WVE Wave Life Sciences Inc. | E | 22/100 | — | — | -35.0% | -1.10% | $715.9M | /wve-vs-dsgn → |
| APMD Apnimed Inc. | D | 44/100 | — | — | — | -5.42% | $721.9M | /apmd-vs-dsgn → |
| ANL Adlai Nortye Group Ltd. | D | 47/100 | — | — | — | -7.10% | $662.0M | /anl-vs-dsgn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Design Therapeutics Inc. (DSGN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$69.8M, operating cash flow of -$54.4M, and free cash flow of -$54.6M (-25.6% YoY). On the balance sheet, DSGN closed FY2025 with $226.2M in total assets against $0 in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$69.8M | -$54.4M | -$54.6M | $226.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$49.6M | -$43.1M | -$43.4M | $252.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$66.9M | -$58.6M | -$58.6M | — | — |
As of 2026-11-02, Design Therapeutics Inc. (NASDAQ: DSGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $10.68 (-3.44% 1D, market cap $692.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DSGN ranks #675 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DSGN carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.1%. By comparison, GYRE (Gyre Therapeutics Inc.) holds a D grade (47/100 RQD, P/E 72.3x, ROIC 25.4%, cap $714.8M) and WVE (Wave Life Sciences Inc.) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).
Per DSGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001807120), Design Therapeutics Inc. generated $0 in revenue, -$69.8M in net income, and -$54.6M in free cash flow against $226.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
DSGN last traded at $10.68 (-3.44% on volume of 249,553 shares), positioning the stock -15.10% below its 50-day simple moving average ($12.58) and -12.24% below its 200-day simple moving average ($12.17). Across its 52-week range of $6.16 to $17.25, DSGN sits at the 40.8% percentile with a 14-day RSI of 47.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.35 to $12.01).
Why DSGN Stock dropped -3.44% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, DSGN scores 35 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -32.1%; FCF yield -7.88%), Whale 13F Flow at 6/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 5/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 13/20 (Altman Z 26; Piotroski F 2/9; Debt/Equity 0.5).
The lowest-scoring pillars are Insider Conviction and Fundamental Cash Engine. For a prospective investor, the score signals that the company is not currently generating cash from operations and that its negative ROIC and FCF yield put the equity valuation on expectations of future clinical or regulatory outcomes rather than current earnings. The Forensic Balance Sheet pillar is the relative bright spot, with a high Altman Z-Score and modest Debt/Equity, which suggests balance-sheet risk is comparatively contained. The Piotroski F-Score of 2/9 is weak, however. The Whale 13F Flow pillar is moderate, and the Insider Conviction pillar is low, which means the source data does not show strong insider-led confidence. Upside drivers would depend on events not quantified in the source data; valuation tradeoffs are that the stock trades without positive earnings to anchor a multiple. This brief is educational and not personalized financial advice.
Per the profile, Design Therapeutics Inc. (DSGN) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company has a market capitalization of $0.7B. Per the profile, the source data does not describe its products, customers, or revenue model. Revenue is reported as $0.0M in each financial period provided.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-79.5M | $-69.8M | N/A | $-54.6M | $16.9M | N/A |
| FY 2024 | $0.0M | $-62.4M | $-49.6M | N/A | $-43.4M | $22.6M | N/A |
| FY 2023 | $0.0M | $-78.2M | $-66.9M | N/A | $-58.6M | N/A | N/A |
Per the SEC financials, reported revenue is $0.0M across the three periods, with operating losses of $-79.5M (FY 2025), $-62.4M (FY 2024), and $-78.2M (FY 2023). Per the market data, gross, operating, and net margins are each 0%, and ROIC is -32.1%. Per the Roarable RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Cash was $16.9M at FY 2025 and $22.6M at FY 2024, with FCF of $-54.6M and $-43.4M respectively.
The butterfly supply-chain graph reports a supply_chain value of NONE, with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Design Therapeutics Inc. (DSGN) • Click "Debate This Headline" to argue it in the Roar Pit below
Seeking Alpha report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Singapore report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Australia report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.
Welcome to the DSGN (Design Therapeutics Inc.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on DSGN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Design Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on DSGN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $11.06 (52-wk range $6.16 - $17.25), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).